ARTICLE SUMMARY:
A graphical look at FDA novel device approvals, 510(k)s, and PMA supplements during the first quarter of 2026.
FDA had an active Q1 in authorizing novel devices, particularly via the original PMA and panel-track PMA supplement pathways.
